Department of Urology, Knuppe Molecular Urology Laboratory, University of California, San Francisco, CA, USA.
BJU Int. 2010 Dec;106(11):1775-81. doi: 10.1111/j.1464-410X.2010.09268.x.
To study whether long-term treatment with oestrogen (E(2) ), selective E(2) receptor modulators (SERMs), or growth hormone (GH) can prevent the development of abnormal voiding patterns during filling cystometry (CMG) in a postpartum, ovariectomized (Ovx) female rat.
Immediately after spontaneous delivery, 60 primiparous Sprague-Dawley rats were randomly divided into six equal groups. One group served as uninjured sham controls and five groups underwent intravaginal balloon dilatation. On day seven, previously dilated rats underwent bilateral Ovx and implantation of a subcutaneous hormone-delivery pump. The five treatment groups received normal saline (control), E(2) , raloxifene, levormeloxifene, or GH for 7 weeks. Conscious CMG was performed 7 weeks after Ovx. Urethral sphincter tissue was harvested for elastin immunohistochemistry and real-time polymerase chain reaction of α(1A) -adrenoceptor mRNA.
No abnormal voiding patterns were detected in the group treated with GH. The E(2) , raloxifene and levormeloxifene groups had greater detrusor overactivity and urethral relaxation incontinence than control rats. The raloxifene group had a significantly lower baseline bladder pressure and opening pressure. GH-treated rats had higher elastin content in the urethra. Urethral α(1A) -adrenoceptor mRNA concentration was significantly lower in the SERM-treated rats compared with controls.
GH prevents the development of abnormal voiding patterns during filling CMG in a rat model of parturition-induced incontinence; E(2) and SERMs may worsen voiding patterns.
研究长期使用雌激素（E(2)）、选择性雌激素受体调节剂（SERMs）或生长激素（GH）能否预防产后去卵巢（Ovx）雌性大鼠充盈性膀胱测压（CMG）期间排尿模式异常的发展。
60 只初产的 Sprague-Dawley 大鼠在自然分娩后立即随机分为 6 组。一组作为未受伤的假对照组，五组进行阴道球囊扩张。第 7 天，先前扩张的大鼠接受双侧 Ovx 和皮下激素输送泵植入。五组治疗组分别接受生理盐水（对照组）、E(2)、雷洛昔芬、左洛昔芬或 GH 治疗 7 周。Ovx 后 7 周进行清醒 CMG。采集尿道括约肌组织进行弹力蛋白免疫组化和α(1A) -肾上腺素能受体 mRNA 的实时聚合酶链反应。
GH 治疗组未检测到异常排尿模式。E(2)、雷洛昔芬和左洛昔芬组比对照组有更大的逼尿肌过度活动和尿道松弛性尿失禁。雷洛昔芬组的基础膀胱压和开口压明显降低。GH 治疗组的尿道弹力蛋白含量较高。与对照组相比，SERMs 治疗组的尿道α(1A) -肾上腺素能受体 mRNA 浓度明显降低。
GH 可预防分娩诱导性尿失禁大鼠模型 CMG 充盈期间排尿模式异常的发生；E(2)和 SERMs 可能会加重排尿模式。
